GCF BULLETIN

Partners for Life -- GCF & Gynecologic Cancer Research

Several GCF-funded projects have probed into the origins of ovarian cancer. Studies of Beth Karlan, MD (1995 recipient of Karin Smith Award), further characterized a novel, ovarian inhibitory substance that downregulates proliferation and triggers apoptosis in ovarian epithelial cells. Research by Andrew Berchuck, MD (1997 recipient of Karin Smith Award), and Richard Buller, MD (1997 recipient of Florence and Marshall Schwid Award), is further clarifying the role of BRCA genes and their complex relationship with other genes that are important in the development of ovarian cancer. Insight from these endeavors will lead to new ways to prevent, screen and treat ovarian cancer.

Some of the most exciting treatments being investigated for cancer are in the area of gene therapy. GCF is supporting translation efforts by Stephen Rubin, MD (1996 recipient of Karin Smith Award), to investigate adenovirus-mediated HSV thymidine kinase gene therapy for ovarian cancer. Jean Hurteau, MD (1997 recipient of Eva Metzger Award), is developing an innovative gene therapy strategy for ovarian cancer designed to inhibit cyclin-dependent kinases. Developing new treatment paradigms with GCF-supported translational research will lead to an improved outcome for ovarian cancer patients.

GCF has also supported research in issues other than ovarian cancer that are of equal importance. Terri Cornelison, MD (1995 recipient of GCF/NCI Research Training Fellowship), is investigating the relationship of growth factor and cytokine expression with radiation-induced fibrosis. Work by Jeffrey Fowler, MD (1995 recipient of Surgery Research Award), has demonstrated adhesion formation to be similar in animal models undergoing laparascopic lymphadenectomy when compared to those who have had a node resection via an extraperitoneal approach. Studies such as this are likely to play a large role in how cervical cancer is surgically staged in the near future. On the clinical front, T. Scott Jennings, MD (1996 recipient of Surgery Research Award), is performing a comparative study of crystalloid versus albumin replacement in ovarian cancer patients with ascites. Preliminary results of this trial have demonstrated the utility of bioimpedence methodology in prospectively identifying massive fluid shifts in advanced stage ovarian cancer patients.

Continuing the legacy of supporting novel gynecologic cancer research is important to the GCF. The GCF Executive Committee approved funding for a new grant to be awarded this year. With the generosity of its supporters, GCF will be able to continue to expand its research activities.

Gynecologic cancer research and GCF -- partners for life, partners for the lives of our patients. Be a partner in this important GCF mission.

Back